Class IA PI3K regulatory subunits: p110-independent roles and structures

被引:48
|
作者
Fox, Millie [1 ]
Mott, Helen R. [1 ]
Owen, Darerca [1 ]
机构
[1] Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England
关键词
INCREASED INSULIN SENSITIVITY; TUMOR-SUPPRESSOR GENE; TYROSINE KINASE ACK; PHOSPHOINOSITIDE; 3-KINASE; PHOSPHATIDYLINOSITOL; P85-ALPHA SUBUNIT; CATALYTIC SUBUNIT; MICE LACKING; PI-3; KINASE; NEGATIVE REGULATION;
D O I
10.1042/BST20190845
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The phosphatidylinositol 3-kinase (PI3K) pathway is a critical regulator of many cellular processes including cell survival, growth, proliferation and motility. Not surprisingly therefore, the PI3K pathway is one of the most frequently mutated pathways in human cancers. In addition to their canonical role as part of the PI3K holoenzyme, the class IA PI3K regulatory subunits undertake critical functions independent of PI3K. The PI3K regulatory subunits exist in excess over the p110 catalytic subunits and therefore free in the cell. p110-independent p85 is unstable and exists in a monomer-dimer equilibrium. Two conformations of dimeric p85 have been reported that are mediated by N-terminal and C-terminal protein domain interactions, respectively. The role of p110-independent p85 is under investigation and it has been found to perform critical adaptor functions, sequestering or influencing compartmentalisation of key signalling proteins. Free p85 has roles in glucose homeostasis, cellular stress pathways, receptor trafficking and cell migration. As a regulator of fundamental pathways, the amount of p110-independent p85 in the cell is critical. Factors that influence the monomer-dimer equilibrium of p110-independent p85 offer additional control over this system, disruption to which likely results in disease. Here we review the current knowledge of the structure and , functions of p110-independent class IA PI3K regulatory subunits.
引用
收藏
页码:1397 / 1417
页数:21
相关论文
共 50 条
  • [31] Novel developmental roles of class IA phosphatidylinositol 3-kinase (PI3K) revealed by graded genetic activation of the catalytic p110α subunit in human induced pluripotent stem cells
    Madsen, R.
    Knox, R.
    Semple, R.
    [J]. FEBS JOURNAL, 2017, 284 : 126 - 126
  • [32] The PI3K p110δ Regulates Expression of CD38 on Regulatory T Cells
    Patton, Daniel T.
    Wilson, Marcus D.
    Rowan, Wendy C.
    Soond, Dalya R.
    Okkenhaug, Klaus
    [J]. PLOS ONE, 2011, 6 (03):
  • [33] Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling
    Chaussade, Claire
    Rewcastle, Gordon W.
    Kendall, Jackie D.
    Denny, William A.
    Cho, Kitty
    Gronning, Line M.
    Chong, Mel Ling
    Anagnostou, Sasha H.
    Jackson, Shaun P.
    Daniele, Nathalie
    Shepherd, Peter R.
    [J]. BIOCHEMICAL JOURNAL, 2007, 404 : 449 - 458
  • [34] A class IA PI3K controls inflammatory cytokine production in human neutrophils
    Fortin, Carl F.
    Cloutier, Alexandre
    Ear, Thornin
    Sylvain-Prevost, Stephanie
    Mayer, Thomas Z.
    Bouchelaghem, Rim
    McDonald, Patrick P.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2011, 41 (06) : 1709 - 1719
  • [35] PI3K activation is enhanced by FOXM1D binding to p110 and p85 subunits
    Qi Wang
    Pingzhao Zhang
    Wei Zhang
    Xin Zhang
    Jianfeng Chen
    Peipei Ding
    Luying Li
    Xinyue Lv
    Ling Li
    Weiguo Hu
    [J]. Signal Transduction and Targeted Therapy, 5
  • [36] PI3K activation is enhanced by FOXM1D binding to p110 and p85 subunits
    Wang, Qi
    Zhang, Pingzhao
    Zhang, Wei
    Zhang, Xin
    Chen, Jianfeng
    Ding, Peipei
    Li, Luying
    Lv, Xinyue
    Li, Ling
    Hu, Weiguo
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [37] The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer
    Zhang, Lei
    Li, Yidong
    Wang, Qianchao
    Chen, Zhuo
    Li, Xiaoyun
    Wu, Zhuoxun
    Hu, Chaohua
    Liao, Dan
    Zhang, Wei
    Chen, Zhe-Sheng
    [J]. MOLECULAR CANCER, 2020, 19 (01)
  • [38] The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer
    Lei Zhang
    Yidong Li
    Qianchao Wang
    Zhuo Chen
    Xiaoyun Li
    Zhuoxun Wu
    Chaohua Hu
    Dan Liao
    Wei Zhang
    Zhe-Sheng Chen
    [J]. Molecular Cancer, 19
  • [39] LPAR5 promotes thyroid carcinoma cell proliferation and migration by activating class IA PI3K catalytic subunit p110β
    Zhao, Wei-Jun
    Zhu, Liu-Lian
    Yang, Wei-Qiang
    Xu, Shuai-Jun
    Chen, Jie
    Ding, Xiao-Fei
    Liang, Yong
    Chen, Guang
    [J]. CANCER SCIENCE, 2021, 112 (04) : 1624 - 1632
  • [40] A new class of selective inhibitors of the p110-alpha isoform of PI3K as cancer drugs
    Denny, William
    Kendall, Jackie
    Rewcastle, Gordon
    Shepherd, Peter
    Flanagan, Jack
    Baguley, Bruce
    Kestell, Phil
    Giddens, Anna
    Tsang, Sophia
    Marshall, Andrew
    [J]. CANCER RESEARCH, 2009, 69